Cancer Genetics Expands Next-Generation Sequencing Capabilities in India Through Launch of Solid Tumor Hotspot Panel for Biop...
April 21 2015 - 7:30AM
> Over 370,000 patients in India develop solid tumor based
cancers annually and are in need of more comprehensive genomic
profiling
> The NGS panel assesses mutations across 50 actionable and
clinically validated oncogenes and tumor suppressor genes with a
higher level of sensitivity and specificity than existing
methods
> Cancer Genetics will create a genomic database and
information exchange of cancer hotspots that will help clinicians
and researchers personalize and improve patient outcomes throughout
India and Asia
Cancer Genetics Inc. (Nasdaq:CGIX) ("CGI" or "the Company")
announced today that Cancer Genetics India (CG India) has launched
a Next-Generation Sequencing (NGS) based panel targeting the five
most common solid tumors: breast, colorectal, lung, skin, and
ovarian cancer for the Indian and broader Asian markets. The
NGS-based panel provides a comprehensive genomic assessment of
cancer mutations, with dramatically increased sensitivity compared
to other testing methodologies, and can be applied to over 370,000
patients annually in India alone. The NGS panel covers over 2,800
clinically validated, common cancer mutations and can be used from
as little as 10 nanograms of DNA from a variety of sample types,
including fresh frozen or formalin-fixed paraffin-embedded (FFPE)
tissue.
With more than 1 million new cases of cancer diagnosed in India
each year, there is a significant need for NGS based comprehensive
testing that provides both cost-savings and increased accuracy over
other technologies by assessing a comprehensive number of genetic
mutations in a single test. The tests will also help CG India in
its strategic initiative to generate a library of critical,
actionable genomic data that can be used by clinicians for improved
patient management and by researchers in India and worldwide to
develop more targeted therapeutics. The International Agency for
Research on Cancer (IARC) based in France predicts that the number
of new annual cancer cases in India will double in the next 20
years only heightening the need for improved technology to help
diagnose and manage cancers earlier and more comprehensively.
"Cancer Genetics India's NGS tumor hotspot panel will allow
clinicians in India the capability to access the genomic
information necessary to improve the diagnosis and management of
patients with common cancers," said Dr. Vidudala Prasad, Ph.D.,
Head of Research and Development at Indo American Cancer Hospital
in Hyderabad, India. "It also offers valuable genomic insights for
investigators working on oncology-focused clinical trials."
CG India is now one of few companies in India that is making
this NGS technology and mutation hotspot panel available for use by
oncologists, biopharmaceutical companies, and research
organizations. Panna Sharma, CEO of Cancer Genetics, Inc.
commented: "There is a critical need in India and Asia for
high-quality assessment of cancer that is comprehensive,
genomically-guided and supported with state of the art
bioinformatics. The clinical and research community will find
tremendous value in both the NGS panel and in our genomic database
which we expect will be an invaluable tool in the improvement of
cancer outcomes for patients and in the acceleration of novel
discoveries into the marketplace."
CG India is also in discussions with a number of biopharma and
research companies in the formation of strategic collaborations and
partnerships to use the NGS hotspot technology for discovery and
accelerated research. The NGS panel addresses a significant,
underserved and growing market, and is expected to contribute to CG
India's overall growth.
The use of the NGS hotspot panel will enable the collection of a
large library of genomic data that can be used to improve the
quality and accuracy of clinical research and discovery efforts.
Mr. Sharma added: "CG India is among the first companies to launch
NGS testing in India. This new panel further establishes us as a
leader in DNA based diagnostics in India. With the launch of this
new panel, we are in a unique position to deepen our collaborations
and partnerships with major cancer centers, academic government
institutions, and biopharma companies focused on oncology
research."
About Cancer Genetics
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer
diagnostics, servicing some of the most prestigious medical
institutions in the world. Our tests target cancers that are
difficult to diagnose and predict treatment outcomes. These cancers
include hematological, urogenital and HPV-associated cancers. We
also offer a comprehensive range of non-proprietary
oncology-focused tests and laboratory services that provide
critical genomic information to healthcare professionals, as well
as biopharma and biotech companies. Our state-of-the-art reference
labs are focused entirely on maintaining clinical excellence and
are both CLIA certified and CAP accredited and have licensure from
several states including New York State. We have established strong
research collaborations with major cancer centers such as Memorial
Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National
Cancer Institute.
For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward Looking Statements: This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements pertaining
to future financial and/or operating results, future developments
in research, technology, clinical development and potential
opportunities for Cancer Genetics, Inc. tests and services, along
with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical
fact (including, but not limited to, statements that contain words
such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, risks
of cancellation of customer contracts or discontinuance of trials,
uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, maintenance
of intellectual property rights and other risks discussed in the
Company's Form 10-K for the year ended December 31, 2014 along with
other filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. Cancer
Genetics disclaims any obligation to update these forward-looking
statements.
CONTACT: Media Relation
Sandeep Kalelkar, Ph.D.
Cancer Genetics, Inc.
919-653-5543
media@cgix.com
or
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Info@redchip.com
Investor Relations
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Sep 2023 to Sep 2024